Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001257

Levetiracetam impurity D

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(2R)-2-(2-Oxopyrrolidin-1-yl)butanamide, (R)-Etiracetam

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C8H14N2O2
Numéro CAS:
103765-01-1
Poids moléculaire :
170.21
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

levetiracetam

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1

Clé InChI

HPHUVLMMVZITSG-ZCFIWIBFSA-N

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1359404

Levetiracetam, United States Pharmacopeia (USP) Reference Standard

1359437

(S)-(+)-2-Aminobutanmide hydrochloride, United States Pharmacopeia (USP) Reference Standard

1359415

Levetiracetam Racemic Mixture, United States Pharmacopeia (USP) Reference Standard

1359426

Levetiracetam Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0001253

Levetiracetam, European Pharmacopoeia (EP) Reference Standard

Y0001256

Levetiracetam impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001254

Levetiracetam impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000659

Pyrrolidone, European Pharmacopoeia (EP) Reference Standard

PHR1447

Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001962

(R)-(+)-α-Methylbenzylamine, European Pharmacopoeia (EP) Reference Standard

Y0001948

(S)-(+)-2-Aminobutanmide hydrochloride, European Pharmacopoeia (EP) Reference Standard

PHR2432

(S)-(+)-2-Aminobutanmide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2428

Levetiracetam Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2417

Levetiracetam Racemic Mixture, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Exclamation markEnvironment
GHS07,GHS09

Mention d'avertissement

Warning

Mentions de danger

H302,H319,H411

Classification des risques

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Levetiracetam Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1447

Levetiracetam

Iu V Popov et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(5 Pt 2), 48-52 (2013-06-07)
We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders
[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
S Yamashita et al.
No to hattatsu = Brain and development, 45(1), 64-66 (2013-04-19)
Yavuz Yesilova et al.
Dermatology online journal, 19(2), 12-12 (2013-03-12)
Erythema multiforme is a skin disease, which occurs particularly in the acral region, and is characterized by target-like erythematous macules and papules. Infections play an important role in the etiology of erythema multiforme. Other causes include drugs, vaccination, and hematological
Ellen Mawhinney et al.
Neurology, 80(4), 400-405 (2013-01-11)
Levetiracetam is a broad-spectrum antiepileptic drug (AED) which is currently licensed in the United States and the United Kingdom and Ireland for use as adjunctive treatment of focal-onset seizures and myoclonic seizures or generalized tonic-clonic seizures, occurring as part of
Diego Garbossa et al.
Neurology India, 61(2), 131-137 (2013-05-07)
The effectiveness of antiepileptic prophylaxis in patients with newly diagnosed high-grade glioma is debated. Craniotomy, surgical manipulation and bleeding are believed to favor the onset of seizures and, therefore, perioperative antiepileptic drugs (AEDs) are generally used. Nevertheless, evidence to initiate
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique